ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 39100666

Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.

Huang Z and 4 others. Front Immunol, 2024. Cited by 6 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis. Papers, record 39100666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39100666

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis.
PubMed
Journal
Front Immunol
PubMed
Year
2024
PubMed
Publication types
Meta-Analysis, Journal Article, Systematic Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.68, provisional
iCite
Revised in PubMed
2026-10-02
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huang ZZhilong
2Li CChunyan
3Huang YYanping
4Liang WWeiming
5Tao HHaiyun

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B7-H1 AntigenMajor topic
Colorectal NeoplasmsMajor topic
Immune Checkpoint InhibitorsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Humans
Treatment Outcome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125,139,339Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Clin Cancer Res2014https://conductscience.org/library/papers/25139339PubMed
235,308,232Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient.Front Pharmacol2022https://conductscience.org/library/papers/35308232PubMed
333,264,544Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med2020https://conductscience.org/library/papers/33264544PubMed
433,538,338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
530,376,427Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.J Clin Oncol2019https://conductscience.org/library/papers/30376427PubMed
628,404,093Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Lancet Gastroenterol Hepatol2016https://conductscience.org/library/papers/28404093PubMed
727,760,322Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.Cell Rep2016https://conductscience.org/library/papers/27760322PubMed
818,854,571Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).J Clin Oncol2008https://conductscience.org/library/papers/18854571PubMed
932,365,882Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.Cancers (Basel)2020https://conductscience.org/library/papers/32365882PubMed
1028,632,865Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA2017https://conductscience.org/library/papers/28632865PubMed

1 to 10 of 52

See all 52 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42,082,463Multi-omics reveals CXCR4 drives immune escape in colorectal cancer via metabolic reprogramming and immune microenvironment remodeling.Cell Death Dis2026https://conductscience.org/library/papers/42082463PubMed
41,716,430Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors.Health Sci Rep2026https://conductscience.org/library/papers/41716430PubMed
40,950,267Clinical efficacy and predictive indicators of cindilizumab combined with XELIRI protocol in advanced colorectal carcinoma patients.Am J Transl Res2025https://conductscience.org/library/papers/40950267PubMed
40,901,310Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis.World J Clin Oncol2025https://conductscience.org/library/papers/40901310PubMed
40,006,027Phaseolus acutifolius Recombinant Lectin Exerts Differential Proapoptotic Activity on EGFR+ and EGFR- Colon Cancer Cells and Provokes T Cell-Assisted Antitumor Responses in Mice.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40006027PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
VEGFA7,422PubTator's text mininghttps://conductscience.org/library/genes/7422

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39100666

GET https://conductscience.org/api/papers/v1/39100666/references?page=2

API referenceFor AI assistants